Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000723648 | SCV000113310 | uncertain significance | not provided | 2013-05-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000081379 | SCV000717580 | likely benign | not specified | 2018-03-15 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Invitae | RCV001000676 | SCV001097366 | likely benign | MOGS-congenital disorder of glycosylation | 2024-01-04 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001000676 | SCV001157707 | likely benign | MOGS-congenital disorder of glycosylation | 2019-03-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002513829 | SCV003602220 | likely benign | Inborn genetic diseases | 2022-03-02 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV000723648 | SCV004155076 | likely benign | not provided | 2022-12-01 | criteria provided, single submitter | clinical testing | MOGS: BP4, BP7 |